WEKO3
アイテム
{"_buckets": {"deposit": "dc2223fb-feca-4a6d-9898-2815e5364bf8"}, "_deposit": {"created_by": 1, "id": "86451", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "86451"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00086451", "sets": ["2"]}, "author_link": ["1055152", "1055150", "1055155", "1055157", "1055151", "1055154", "1055153", "1055156"], "item_10003_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2022-06", "bibliographicIssueDateType": "Issued"}, "bibliographic_titles": [{"bibliographic_title": "Nuclear Medicine and Biology"}]}]}, "item_10003_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives: Transmembrane AMPA receptor regulatory proteins subtype γ8 (TARP γ8) exhibits regiospecific expression in the brain, which could serve as a potential therapeutic target for central nervous system disorders with high selectivity. Based on two potent and selective TARP γ-8 antagonists, 6-(2-cyclobutyl-5-methyl-3H-imidazo[4,5-b]pyridin-3-yl)benzo[d]thiazol-2(3H)-one (compound 8) and (2-cyclobutyl-3-(1H-indazol-5-yl)-5-methyl-3H-imidazo[4,5-b]pyridine (compound 15), we perform the radiosynthesis of its 11C-isotopologue and conduct preliminary evaluation to test the feasibility of imaging TARP γ-8 dependent receptors in vitro and in vivo.\nMethods: The synthesis of precursor 22 was shown in Scheme 1A. Initially, the preparation of the compound 19 was achieved in 81% through the SN2 coupling reaction between 6-aminobenzo[d] thiazol-2(3H)-one 2 and 2,6-dibromo-3-nitropyridine in the presence of NEt3. As follows, the mild condition of Fe/NH4Cl instead of Pd/C-H2 system was used in the reduction of nitro group to amine in the terms of sensitive bromo-substitution group of 19, which offered 6-((3-Amino-6-bromopyridin-2-yl)amino)benzo[d]thiazol-2(3H)-one 20 with high chemoselectivity in the yield of 76%. The compound 20 then underwent condensation with cyclobutanecarbaldehyde, followed by oxidation, to afford benzothiazolone 21. The subsequent Pd catalyzed Stannylation generated 22 as a precursor in the yield of 36%. Similarly, the other precursor 27 was obtained from commercially available starting material of 1H-indazol-5-amine 10 in 6 steps (Scheme 1B). The radiosynthesis of [11C]8 and [11C]15 from the corresponding precursors were carried out. As a result, [11C]8 and [11C]15 were obtained in an average radiochemical yield (RCY) of 9% and 22%, respectively, with high radiochemical purity (\u003e99%) and excellent molar activity (\u003e150 GBq/μmol). The autoradiography (ARG) studies for [11C]8 were conducted to evaluate target binding in vitro. Figure 1 indicated heterogeneous regional distribution pattern from high to low in the order of hippocampus, cerebral cortex, striatum, thalamus and cerebellum in [11C]8 ARG studies. The distribution profile was consistent with the mRNA expression pattern of TARP γ-8 with the highest signal level in the region of the hippocampus and the lowest level in the cerebellum. For ligand [11C]8, blocking studies by compound 8 (1 µM) led to markedly decrease of the bound radioactivity in the TARP γ8 rich hippocampus.\nResults: The radioligand [11C]8 and [11C]15 were synthesized in 9% and 22% radiochemical yield (RCY) respectively, based on the starting [11C]CO2 at the end-of-synthesis with \u003e99% radiochemical purity (n = 5). Both of their molar activities were greater than 150 GBq/µmol (4.1 Ci/µmol). No sign of radiolysis was observed up to 90 min after re-formulation for both of [11C]8 and [11C]15. In ARG studies, the radioligand [11C]8 exhibited great heterogeneous regional distribution pattern (high uptake in hippocampus while low uptake in cerebellum).\nConclusion: We have evaluated the radiochemical method to prepare 11C-labeled labeled TARP ɣ-8 antagonists based on Stille coupling-based labeling methodology. Ultimately, the desired compounds [11C]8 and [11C]15 were labeled by [11C]CH3I in high radiochemical yield (9% and 22% respectively), high molar activity (\u003e150 GBq/μmol) and high radiochemical purity (\u003e99%).", "subitem_description_type": "Abstract"}]}, "item_10003_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Elsevier Ltd."}]}, "item_10003_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0969-8051", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "A. Yu, Qingzhen"}], "nameIdentifiers": [{"nameIdentifier": "1055150", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsushi, Kumata"}], "nameIdentifiers": [{"nameIdentifier": "1055151", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Lee Collier, Thomas"}], "nameIdentifiers": [{"nameIdentifier": "1055152", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tomita, Susumu"}], "nameIdentifiers": [{"nameIdentifier": "1055153", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "1055154", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Liang, Steven"}], "nameIdentifiers": [{"nameIdentifier": "1055155", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsushi, Kumata", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1055156", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1055157", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference paper", "resourceuri": "http://purl.org/coar/resource_type/c_5794"}]}, "item_title": "Radiosynthesis of 6-(2-cyclobutyl-5-(methyl-11C)-3H-imidazo[4,5-b]pyridin-3-yl)benzo[d]thiazol-2(3H)-one and (2-cyclobutyl-3-(1H-indazol-5-yl)-5-[11C]methyl-3H-imidazo[4,5-b]pyridine for imaging γ-8 dependent transmembrane AMPA receptor regulatory protein", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Radiosynthesis of 6-(2-cyclobutyl-5-(methyl-11C)-3H-imidazo[4,5-b]pyridin-3-yl)benzo[d]thiazol-2(3H)-one and (2-cyclobutyl-3-(1H-indazol-5-yl)-5-[11C]methyl-3H-imidazo[4,5-b]pyridine for imaging γ-8 dependent transmembrane AMPA receptor regulatory protein"}]}, "item_type_id": "10003", "owner": "1", "path": ["2"], "permalink_uri": "https://repo.qst.go.jp/records/86451", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-06-08"}, "publish_date": "2022-06-08", "publish_status": "0", "recid": "86451", "relation": {}, "relation_version_is_last": true, "title": ["Radiosynthesis of 6-(2-cyclobutyl-5-(methyl-11C)-3H-imidazo[4,5-b]pyridin-3-yl)benzo[d]thiazol-2(3H)-one and (2-cyclobutyl-3-(1H-indazol-5-yl)-5-[11C]methyl-3H-imidazo[4,5-b]pyridine for imaging γ-8 dependent transmembrane AMPA receptor regulatory protein"], "weko_shared_id": -1}
Radiosynthesis of 6-(2-cyclobutyl-5-(methyl-11C)-3H-imidazo[4,5-b]pyridin-3-yl)benzo[d]thiazol-2(3H)-one and (2-cyclobutyl-3-(1H-indazol-5-yl)-5-[11C]methyl-3H-imidazo[4,5-b]pyridine for imaging γ-8 dependent transmembrane AMPA receptor regulatory protein
https://repo.qst.go.jp/records/86451
https://repo.qst.go.jp/records/86451fb161aec-c929-482d-890e-9cadac8b1579
Item type | 会議発表論文 / Conference Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-06-08 | |||||
タイトル | ||||||
タイトル | Radiosynthesis of 6-(2-cyclobutyl-5-(methyl-11C)-3H-imidazo[4,5-b]pyridin-3-yl)benzo[d]thiazol-2(3H)-one and (2-cyclobutyl-3-(1H-indazol-5-yl)-5-[11C]methyl-3H-imidazo[4,5-b]pyridine for imaging γ-8 dependent transmembrane AMPA receptor regulatory protein | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_5794 | |||||
資源タイプ | conference paper | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
A. Yu, Qingzhen
× A. Yu, Qingzhen× Katsushi, Kumata× Lee Collier, Thomas× Tomita, Susumu× Zhang, Ming-Rong× Liang, Steven× Katsushi, Kumata× Zhang, Ming-Rong |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives: Transmembrane AMPA receptor regulatory proteins subtype γ8 (TARP γ8) exhibits regiospecific expression in the brain, which could serve as a potential therapeutic target for central nervous system disorders with high selectivity. Based on two potent and selective TARP γ-8 antagonists, 6-(2-cyclobutyl-5-methyl-3H-imidazo[4,5-b]pyridin-3-yl)benzo[d]thiazol-2(3H)-one (compound 8) and (2-cyclobutyl-3-(1H-indazol-5-yl)-5-methyl-3H-imidazo[4,5-b]pyridine (compound 15), we perform the radiosynthesis of its 11C-isotopologue and conduct preliminary evaluation to test the feasibility of imaging TARP γ-8 dependent receptors in vitro and in vivo. Methods: The synthesis of precursor 22 was shown in Scheme 1A. Initially, the preparation of the compound 19 was achieved in 81% through the SN2 coupling reaction between 6-aminobenzo[d] thiazol-2(3H)-one 2 and 2,6-dibromo-3-nitropyridine in the presence of NEt3. As follows, the mild condition of Fe/NH4Cl instead of Pd/C-H2 system was used in the reduction of nitro group to amine in the terms of sensitive bromo-substitution group of 19, which offered 6-((3-Amino-6-bromopyridin-2-yl)amino)benzo[d]thiazol-2(3H)-one 20 with high chemoselectivity in the yield of 76%. The compound 20 then underwent condensation with cyclobutanecarbaldehyde, followed by oxidation, to afford benzothiazolone 21. The subsequent Pd catalyzed Stannylation generated 22 as a precursor in the yield of 36%. Similarly, the other precursor 27 was obtained from commercially available starting material of 1H-indazol-5-amine 10 in 6 steps (Scheme 1B). The radiosynthesis of [11C]8 and [11C]15 from the corresponding precursors were carried out. As a result, [11C]8 and [11C]15 were obtained in an average radiochemical yield (RCY) of 9% and 22%, respectively, with high radiochemical purity (>99%) and excellent molar activity (>150 GBq/μmol). The autoradiography (ARG) studies for [11C]8 were conducted to evaluate target binding in vitro. Figure 1 indicated heterogeneous regional distribution pattern from high to low in the order of hippocampus, cerebral cortex, striatum, thalamus and cerebellum in [11C]8 ARG studies. The distribution profile was consistent with the mRNA expression pattern of TARP γ-8 with the highest signal level in the region of the hippocampus and the lowest level in the cerebellum. For ligand [11C]8, blocking studies by compound 8 (1 µM) led to markedly decrease of the bound radioactivity in the TARP γ8 rich hippocampus. Results: The radioligand [11C]8 and [11C]15 were synthesized in 9% and 22% radiochemical yield (RCY) respectively, based on the starting [11C]CO2 at the end-of-synthesis with >99% radiochemical purity (n = 5). Both of their molar activities were greater than 150 GBq/µmol (4.1 Ci/µmol). No sign of radiolysis was observed up to 90 min after re-formulation for both of [11C]8 and [11C]15. In ARG studies, the radioligand [11C]8 exhibited great heterogeneous regional distribution pattern (high uptake in hippocampus while low uptake in cerebellum). Conclusion: We have evaluated the radiochemical method to prepare 11C-labeled labeled TARP ɣ-8 antagonists based on Stille coupling-based labeling methodology. Ultimately, the desired compounds [11C]8 and [11C]15 were labeled by [11C]CH3I in high radiochemical yield (9% and 22% respectively), high molar activity (>150 GBq/μmol) and high radiochemical purity (>99%). |
|||||
書誌情報 |
Nuclear Medicine and Biology 発行日 2022-06 |
|||||
出版者 | ||||||
出版者 | Elsevier Ltd. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0969-8051 |